Data obtained through freedom of information requests reveals that hundreds of children across England, including some under the age of twelve, have reportedly been prescribed GLP-1 medications such as Wegovy and Mounjaro. These treatments, primarily designed to regulate blood sugar and curb appetite, have increasingly become a focal point in discussions surrounding public health and childhood weight management. Figures from the NHS Business Services Authority show that hundreds of prescriptions were issued to individuals under eighteen, highlighting a growing reliance on pharmacological interventions. Experts like Professor Martin Whyte from the University of Surrey emphasize that young people starting these treatments require comprehensive specialist care, continuous monitoring of growth, puberty, nutrition, and mental health, alongside permanent lifestyle modifications since weight often returns once medication stops. This trend emerges against the backdrop of alarming new government statistics from the National Child Measurement Programme, indicating that childhood obesity in England continues to climb. The findings underline stark health inequalities, showing that obesity rates in the most deprived regions are more than double those recorded in the most affluent areas. Public health advocates point to these deep-seated socio-economic divides as a critical factor that must be addressed alongside any medical treatments. Source: The Independent #Health #Children #Obesity #UK #PublicHealth
Ver más en NewsToday